13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001652044
Total reported value
$99.1B
$99.1B
36 檔
1.3%
In Q2 2025, Alphabet Inc.'s U.S. equity holdings reached a combined market value of $99.1B, distributed across 36 disclosed stock positions.
During Q2 2025, Alphabet Inc.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including ASTS, ARM, FRSH) accounted for 1.3% of total reported equity market value during Q2 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ASTS | Ast Spacemobile Inc | Stock-Tech | 19.57% | -17.66% | — | |
| 2 | ARM | Arm Holdings Plc-adr | Stock-Tech | 14.85% | -6.69% | — | |
| 3 | FRSH | Freshworks Inc-cl A | Stock-Other | 11.32% | -3.07% | — | |
| 4 | PL | Planet Labs Pbc | Stock-Industrials | 9.13% | -23.35% | — | |
| 5 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 7.12% | -7.41% | — | |
| 6 | ✓ | Stock-Other | 6.61% | — | — | ||
| 7 | ✓ | Verve Therapeutics Inc | Stock-Other | 6.40% | — | -1.46% | |
| 8 | GTLB | Gitlab Inc-cl A | Stock-Tech | 5.76% | -1.39% | — | |
| 9 | TEM | Tempus Ai Inc-cl A | Stock-Healthcare | 4.62% | -1.66% | — | |
| 10 | DXCM | Dexcom Inc | Stock-Healthcare | 4.24% | — | — | |
| 11 | PATH | Uipath Inc - Class A | Stock-Tech | 4.22% | -1.86% | — | |
| 12 | PRME | Prime Medicine Inc | Stock-Other | 1.74% | -1.38% | — | |
| 13 | MAZE | Maze Therapeutics Inc | Stock-Other | 1.39% | -0.99% | — | |
| 14 | OSCR | Oscar Health Inc - Class A | Stock-Healthcare | 0.48% | -0.13% | — | |
| 15 | SANA | Sana Biotechnology Inc | Stock-Other | 0.36% | -0.19% | — | |
| 16 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.31% | -0.27% | — | |
| 17 | VERA | Vera Therapeutics Inc | Stock-Other | 0.27% | -0.23% | — | |
| 18 | BEAM | Beam Therapeutics Inc | Stock-Other | 0.26% | -0.18% | — | |
| 19 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.25% | -0.36% | — | |
| 20 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.18% | — | — | |
| 21 | LYEL | Lyell Immunopharma Inc | Stock-Other | 0.12% | -0.15% | — | |
| 22 | SPRO | Spero Therapeutics Inc | Stock-Other | 0.12% | -0.05% | — | |
| 23 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 0.11% | — | — | |
| 24 | WGS | Genedx Holdings CORP | Stock-Other | 0.10% | — | — | |
| 25 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.07% | -0.02% | — | |
| 26 | TCRX | Tscan Therapeutics Inc | Stock-Other | 0.07% | — | — | |
| 27 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.07% | — | — | |
| 28 | BRNS | Barinthus Biotherapeutics Pl | Stock-Other | 0.07% | — | — | |
| 29 | EXK | Exact Sciences CORP | Stock-Materials | 0.06% | — | — | |
| 30 | GUTS | Fractyl Health Inc | Stock-Other | 0.05% | — | — | |
| 31 | HYPR | Hyperfine Inc | Stock-Other | 0.03% | -0.02% | — | |
| 32 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.03% | -0.02% | EXIT | |
| 33 | QNCX | Quince Therapeutics, Inc. | Stock-Other | 0.01% | — | — | |
| 34 | ALEC | Alector Inc | Stock-Other | 0.01% | — | — | |
| 35 | FULC | Fulcrum Therapeutics Inc | Stock-Other | — | — | — | |
| 36 | RGEN | Repligen CORP | Stock-Healthcare | — | — | — |
According to official SEC Form 13F filings, Alphabet Inc. reported a total U.S. public equity portfolio value of $99.1B across 36 disclosed positions in Q2 2025.
During Q2 2025, Alphabet Inc.'s top holdings by market value included ASTS (19.6%)、ARM (14.8%)、FRSH (11.3%). The largest single position, ASTS, represented 19.6% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In Q2 2025, Alphabet Inc. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.